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ABSTRACT
The world pharmaceutical industry has changed tre-
mendously in the last decade. Globalization processes 
reinforce a consolidation of the world pharmaceutical 
industry. Mergers and acquisitions prevail more and 
more as a strategic orientation of numerous world 
pharmaceutical companies. In our research we found 
out that marketing management has been playing an 
increasingly important or even a crucial role in day-to-
day activities and strategic business operations of the 
world pharmaceutical companies. We may point out 
that a rapid consolidation of the world pharmaceutical 
industry is deﬁnitely a market-driven process, one con-
ditioned by typical strategic marketing management 
issues, such as a lack of brand new products, intense 
competitiveness, globalization processes, increased 
global marketing and sales activities, changing struc-
ture of global competitors as well as a furious ﬁght for 
global market shares and customers’ loyalty. We esti-
Ključne riječi:
farmaceutska industrija, tržište, globalizacija, uprav-
ljanje marketingom 
SAŽETAK
Svjetska farmaceutska industrija u posljednjem je 
desetljeću doživjela goleme promjene. Globalizacijski 
procesi potiču na konsolidaciju unutar ove industrije. 
Sve je više svjetskih farmaceutskih poduzeća koja se u 
svojoj strateškoj orijentaciji odlučuju za postupke spa-
janja i preuzimanja. Svojim istraživanjem otkrili smo da 
upravljanje marketingom igra sve važniju, čak i ključnu 
ulogu i u svakodnevnom i u strateškom poslovanju 
globalnih farmaceutskih poduzeća. Mogli bismo istak-
nuti da je ubrzana konsolidacija unutar svjetske farma-
ceutske industrije zasigurno proces koji potiče samo 
tržište, a uvjetuju ga pitanja koja su tipična za strateško 
upravljanje marketingom kao što su nedostatak novih 
proizvoda, jaka konkurencija, globalizacijski procesi, 
povećane aktivnosti na području globalnog mar-
ketinga i prodaje, promjenjiva struktura globalnih 
konkurenata i bespoštedna borba za udjele na glo-
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će u budućim procesima globalizacije i koncentracije 
unutar svjetske farmaceutske industrije upravljanje 
marketingom imati još i važniju ulogu te postati najviši 
strateški prioritet. Neka iskustva i pouke iz globalne 
perspektive svjetske farmaceutske industrije mogli 
bi koristiti i  menadžmentu farmaceutskih poduzeća 
u tranzicijskim zemljama Srednje i Istočne Europe. 
Imajući u vidu trenutni tržišni položaj tih poduzeća, 
mogu se predložiti stanovite smjernice za upravljanje 
marketingom u okviru njihovih politika i strategija up-
ravljanja marketingom. Zaključujemo da najveća pri-
jetnja budućoj strateškoj orijentaciji i uspjehu globalne 
farmaceutske industrije leži upravo u podcjenjivanju i 
potpunom zanemarivanju važnosti pitanja upravljanja 
marketingom.
 
mate that marketing management is to play an even 
more important and, especially, the top priority stra-
tegic role in the future globalization and concentra-
tion processes of the world pharmaceutical industry. 
Some experiences and lessons from the global per-
spective of the world pharmaceutical industry could 
also be useful to the management of pharmaceutical 
companies in the transition countries of the Central 
and Eastern European region. Taking into consider-
ation the current market position of these companies, 
some marketing management guidelines for their 
marketing management policies and strategies could 
be suggested. We conclude that underestimating, or 
even complete neglect of the importance of market-
ing management issues may pose the greatest threat 
to the future strategic orientation and performance of 
the world pharmaceutical industry.
 












We can deﬁne the main characteristics of the world 
pharmaceutical industry as follows: 
• increased globalization,
• changing structure of competition and increased 
competitiveness,
• lack of brand new products, despite increased 
investments into Research & Development (R&D) 
activities,
• increased importance of regulatory issues (registra-
tion, intellectual property rights, litigation),
• fast consolidation and concentration of the world 
pharmaceutical industry,
• increased importance of marketing management,
• development of new therapeutic ﬁelds and tech-
nologies (biotechnology, pharmacogenomics),
• rapid development of global generic markets.
The world pharmaceutical market has undergone tre-
mendous and complex changes in the last few years. 
We may say that the pharmaceutical industry has been 
adapting itself increasingly to market trends and mar-
ket demands. Further strategic development of the 
world pharmaceutical industry shows relatively clearly 
its considerable consolidation and concentration, as 
well as a strong market orientation. A rapid develop-
ment of basic sciences and of the modern technologi-
cal knowledge on the one hand, and qualitative man-
agement of the world pharmaceutical market on the 
other hand have a major impact on day-to-day activi-
ties but even more so on the strategic business opera-
tions of pharmaceutical companies, which compete 
ﬁercely for shares of the world pharmaceutical market. 
The development of a brand new drug (NAS–New Ac-
tive Substance) is estimated to require over $ 1.2 billion 
in investment and takes over 12 years to introduce it 
in the market as a ﬁnished, legally registered and ap-
proved product.1
This is both a very complex and at the same time a 
highly risky job with no ultimate guarantee that the 
potential new product might succeed in the market 
or bring revenues back. If a pharmaceutical company 
wants to achieve market success with a brand new 
product, it needs to invest heavily into marketing and 
sales activities. We may conclude that it is no surprise 
that basic R&D activities, together with marketing 
and sales activities, are the most important strategic 
activities of the world pharmaceutical industry. They 
are deﬁnitely what the major part of investments of 
the pharmaceutical industry is channeled into. Having 
analyzed investment ﬁgures, we have found that the 
largest, most inventive world pharmaceutical compa-
nies invest on average around 16% of their sales into 
R&D and an even larger share, around 25% or more, 
into marketing and sales activities. However, these 
ratios, especially the one for R&D investment, may 
be even higher for specialists, such as biotechnology 
companies and much lower for generic pharmaceuti-
cal companies.2
 
As mentioned, pharmaceutical companies diﬀer ac-
cording to their basic performance and strategic de-
velopment, in turn determining the structure of the 
world pharmaceutical industry. 
We may deﬁne three diﬀerent groups of pharmaceuti-
cal companies:
• pharmaceutical companies which primarily work 
on the basic research and development, and mar-
keting and sales of brand new inventive original 
pharmaceutical products (called originators),
• pharmaceutical companies which primarily work 
on the development and sales of generic products 
(called generic or copycat producers),
• pharmaceutical companies which primarily work on 
the basic research and development of biotechnol-
ogy and pharmacogenomic products, and on the 
technologies of new delivery systems (called spe-
cialists).
2. RESEARCH OBJECTIVES 
Our hypothesis is that marketing management is 
playing an increasingly important role in the perfor-
mance of the world pharmaceutical companies. In our 
research we aim at trying to ﬁnd out how important 

























marketing and marketing management practices are, 
and in what way they correlate directly with the busi-
ness performance of the world pharmaceutical com-
panies. We would like to evaluate the importance of 
marketing management in the strategic orientation of 
pharmaceutical companies and the way in which it 





In 2006, the world pharmaceutical market recorded 
total sales of $ 643 billion and a growth rate of 7%. 
The fastest-growing world markets and regions are the 
markets of China, Central East European region (Russia, 
Poland, Romania) and certain markets of Latin America 
(Brazil, Mexico, Chile). Nevertheless, the world pharma-
ceutical market is estimated to grow at an average 7% 
CAGR (Compounded Annual Growth Rate) till 2013.3
It is estimated that, due to several factors – the expi-
ration of patent protection of some of the best-sell-
ing pharmaceutical products in the most developed 
world markets (major impact is in the United States), 
the worldwide healthcare cost reduction and restruc-
turing as well as the ageing of population and price 
pressures – the world generic markets tend to grow 
even faster, at an average 12% CAGR till 2013.4
Table 1: World pharmaceutical market from 2002 to 
2006
Year Value in billion $ Growth in %
2002   422 9.0
2003   490 16.1
2004   547 11.6
2005   602 10.0
2006   643 7.1
Source: World Review 2007  
The world’s leading pharmaceutical markets in terms 
of sales and the per capita consumption of medicines 
are the United States, Japan and Germany. The U.S. 
share exceeded 40% of the global pharmaceutical 
market in 2006. This reﬂects the fact that the leading 
world pharmaceutical market has some speciﬁc factors 
which distinguish it from other world markets, such as: 
generally free pricing policy of medicines, which is not 
a common issue with other markets (they usually have 
regulated reference pricing systems, especially in the 
European Union), high consumption of medicines, in-
tensive marketing activities, sometimes described as 
“turbo marketing”, as well as tough competition.








1.  USA 272   900
2.  Japan 68   530
3.  Germany 30   365
4.  France 26   400
5. United 
Kingdom 
18   295
6.  Italy 16   275
7.  Canada 14   425
8.  Spain 12   300
9.  Brazil 10   53
10.  Mexico 9   83
Source: own estimation, according to IMS Health
The products themselves are by no means the main 
generators of growth of the world pharmaceutical 
industry. Pharmaceutical companies compete on 
product characteristics and tend to invest heavily into 
marketing activities in an endeavor to gain prescrib-
ers/patient loyalty. Moreover, they compete directly 
with other pharmaceutical companies to conquer 
world market shares. 











For the purpose of better understanding, we deﬁne 
a generic product as a bioequivalent product with 
the same active ingredient as an inventive, original 
one and which is also subject to a standard registra-
tion procedure as the original one; nevertheless, it is 
only legally allowed to be launched upon the ﬁnal 
expiration of all pending intellectual property rights 
(patent expiry). According to this and taking into ac-
count the fact that generic producers do not need to 
invest huge sums of money into basic R&D activities, 
they compete merely, to put it plainly, on the lower 
prices of their products. The most developed and the 
biggest world generic market in terms of sales is the 
generic market of the U.S. itself, which reached close 
to $ 42 billion in sales in 2006 and recorded a growth 
rate of 13%. This exceeded the growth rate of the U.S. 
pharmaceutical market as a whole, which expanded 
by 5% that same year.5
The ten leading world pharmaceutical companies cur-
rently command just over a 42% share of the global 
pharmaceutical market. For a comparison reference, 
this ﬁgure was only 30% ten years ago.6 This is a clear 
sign and proof of how rapidly market consolidation 
and concentration of the world pharmaceutical indus-
try has changed the world pharmaceutical market in 
the last several years. The world pharmaceutical indus-
try has undergone deep changes in the last decade. 
Most notably, strong processes of consolidation and 
concentration have impacted practically all the three 
deﬁned sectors as numerous mergers and acquisitions 
have occurred, resulting in completely new alliances. 
Table 3: Leading world pharmaceutical products in the year 2006 
Position Product/indication/company Sales in billion $
1. Lipitor (atorvastatin), hyperlipidaemia/Pﬁzer 13.6
2. Nexium (esomeprazol), antiulcerant/AstraZeneca 6.7
3. Seretide/Advair (ﬂuticazon+salmeterol), asthma/GSK 6.3
4. Plavix (clopidogrel), prevention of cardiovascular disorders (strokes) /sanoﬁ-
aventis and BMS
5.8
5. Aranesp (darbepoetin alpha), modiﬁed epoetin/Amgen 5
Source: own estimation, according to IMS Health
Table 4: Leading world pharmaceutical companies in the year 2006*
Position Company Country of origin Sales in billion $ World market share in %
1. Pﬁzer  U.S. 45.1 7.0
2. GlaxoSmithKline  United Kingdom 37.1 5.8
3. sanoﬁ-aventis  France 36.9 5.7
4. Roche Switzerland 27.3 4.2
5. AstraZeneca United Kingdom 26.5 4.1
6. Novartis Switzerland 23.5 3.7
7. Johnson&Johnson U.S. 23.3 3.6
8. Merck&Co U.S. 22.6 3.5
9. Wyeth U.S. 16.8 2.6
10. Eli Lilly U.S. 15.7 2.4
* according to consolidated sales of pharmaceuticals and vaccines
Source: own estimation according to oﬃcial company data





























country of origin 
Sales in 
billion $
1. Teva, Israel 8.4
2. Sandoz, Germany 5.9
3. Barr Pharmaceuticals, USA 2.5
4. Merck Generics, Germany 2.4
5. Ratiopharm, Germany 2.1
6. Watson, USA 1.9
7. Actavis, Iceland 1.8
8. Stada, Germany 1.6
9. Mylan, USA 1.5
10. Ranbaxy, India 1.3
Source: own estimation, according to oﬃcial company 
data
It can be argued that competitiveness has increased 
tremendously and very quickly so there is an urgent 
need for pharmaceutical companies to behave in a 
good, sharp and speedy manner, as global customers 
have had more and more options to choose from and 
it is getting more and more diﬃcult to count on their 
everlasting loyalty. 
We have analyzed and scrutinized an entire business 
chain in the pharmaceutical performance and found 
that, for a proper understanding and valuation, one 
needs to monitor the “Whole 11-P chain (product, pat-
ent, price, place, promotion, payers, providers, physi-
cians, pharmacists, pharmaceutical industry, patients)”7 
in order to get a relevant picture of the whole process, 
departing from a rough idea - what is to be a future 
medicine - till giving the ﬁnal user (patient) proper ail-
ment relief. 
Figure 1: 11-P chain 
Source: Kesič, D.: Strategic alliances as a reality in the pharmaceuticals, 2nd MBA scientiﬁc meeting – Strategic 
alliances as Slovenia joins EU membership, March 16th, 2000, FEB Maribor, Work in the Proceedings, Institute for 
Management Development and Educational Association MBA club, Maribor, Slovenia, 2000. 
We can forecast that, taking into account the men-
tioned factors, further consolidation and concentration 
of the world pharmaceutical industry is realistically to 
be expected. We expect the formation of even big-
ger pharmaceutical concerns in all the three sectors 
of the pharmaceutical industry. Also, a further lack of 
new products is expected, alongside greatly increas-
ing competitiveness and a furious fight for market 
shares and global customers’ loyalty. However, we 
underline that the marketing way of thinking and 
performing and a prudent market orientation of the 
world pharmaceutical companies will further split suc-
cessful pharmaceutical companies from unsuccessful 
ones. Why is that so? Simply, we may argue that the 
marketing way of thinking and the marketing manage-
ment performance is an urgent need even today, not 
to mention tomorrow and in the months and years 
to come in a highly globalized, complex, demanding, 
uncertain and competitive world.
4. IMPACT OF THE 
GLOBALIZATION 
PROCESS
We can state that globalization is almost a synonym for 
a modern economy. Globalization would not be pos-
sible without fast and profound technological achieve-
ments and changes. Nowadays, global competition is 
mostly based on the knowledge and technology, and 
on the ability to serve customers fast and repeatedly. 
Knowledge (technology), people and markets have 
become increasingly the basic and the most impor-
tant competition factors among companies as well as 
among countries. Globalization has become almost 
a synonym for economic liberalization and the fore-
most opening of the world economies. The most ac-
tive subjects of the globalization process are deﬁnitely 











transnational or multinational companies. Through 
their operations they actually manage and control 
the international exchange of goods, diminishing its 
freedom as the largest part is conducted among mul-
tinational companies (inter-company goods or service 
exchange). All this has changed the structure of the 
world market, which has become almost predomi-
nantly oligopolistic. However, market competition has 
changed as well. We even talk about the competition 
advantages of particular companies. The OECD deﬁnes 
globalization as a “spreading and deepening of the 
companies’ performance with the target to produce 
and sell goods or services on multiple markets.”8 A 
later deﬁnition of globalization from the OECD says 
that we may deﬁne globalization more precisely “as a 
developing pattern of international business coopera-
tion, which includes investments, trade and contractor 
ways of cooperation, and targets the development of 
products, production, procurement and marketing.”9 
Such international operations enable the companies 
to conquer new markets and use their technological 
and organizational advantages to lower the costs and 
the risks. Globalization is thus strongly related to in-
creased mobility and competition. The main drivers 
of globalization are deﬁnitely transnational or multi-
national companies. 
We emphasize that the following characteristics are 
significant for their performance, especially taking 
into consideration the multinational pharmaceutical 
companies:
• multinational companies have a good market po-
sition on the most important and strategic world 
markets,
• they globally integrate and connect their business 
operations, so a national identity is no longer im-
portant,
• they apply a ﬂexible purchasing strategy,
• they have built a global network of production 
plants,
• they have organized their R&D activities globally,
• they have invested considerably into an eﬃcient 
global marketing organization, which supports 
their strong market orientation and a strategic fo-
cus on customers.
We can say that globalization in its core meaning is a 
complex, market-conditioned world process, which is 
related to and driven by all the elements of the mar-
keting way of thinking and acting, by sudden and fast 
changes in the way that business is conducted, along 
with increasing competition and competitiveness, in 
an attempt to optimally identify changing needs of 
the world customers and gain the ability to satisfy their 
long-term needs. It is very important to keep in mind 
that one needs to know how to detect the needs of cus-
tomers and satisfy them in the long run. We would like 
to emphasize the fact that customers should be treated 
as the most precious asset of a company. This is why we 
stress that globalization is a market-driven process. 
Therefore, it is crucial in the process of globalization 
to be strongly market-oriented, to be fast, to have 
loyal customers, to be innovative, to have knowledge, 
to learn fast and to have proper information. Bartlett 
and Ghoshal underlined that successful companies of 
today and tomorrow are those which are “able at the 
same time to satisfy local market needs, to increase 
global successfulness, to strive for constant innovative-
ness and constant global learning”.10
Drucker mentioned the ﬁve most important elements 
of development which would inﬂuence greatly the 
strategies, structure and performance of future com-
panies:11
•  economic relations would be formed among trade 
blocs instead of countries,
•  business operations would be more and more a 
matter of strategic alliances, integrated into the 
world economy,
•  restructuring of business would intensify and be-
come more globalized, it would be important to 
have information and knowledge,
•  strategic management of companies would be 
decisive for a competitive success,
•  intense market orientation of companies would be 
a core advantage in achieving an edge over com-
petitors.
Globalization is deﬁnitely an irreversible process and 
without intensive international operations companies 

























would not progress in the modern world. However, 
in order to be more successful, one must be capable 
to produce certain products more cheaply with the 
help of a better process technology while also being 
better-organized and market-oriented so as to react 
more quickly to market signals and demands, and to 
respond better and faster to customers’ needs than its 
competitors. Also, we may say that the most important 
element of competitiveness is innovativeness – a ca-
pability to create new products and technologies, and 







The world pharmaceutical industry has undergone in-
tensive processes of concentration and consolidation 
over a period of more than 20 years. As we argue that 
R&D and marketing activities are the two most impor-
tant and strategic priorities of modern pharmaceutical 
companies, into which the greatest portion of funds 
has been invested too, we may say that the main and 
key strategic reasons for the processes of consolidation 
of the world pharmaceutical industry, according to our 
research work, are the following:
• lack of new products to drive further sales 
growth,
• fast processes of globalization of the world econo-
my,
• huge investments needed for R&D,
• global marketing and sales activities which require 
massive investments as well, 
• increased competitiveness,
• changing structure of competition,
• world reforms of health care systems,
• growing importance of regulatory issues (registra-
tions, intellectual property, litigation).
According to the results of our research, there have 
been more than 15,000 alliances in the world phar-
maceutical industry in the last decade.12 We found 
that consolidation and alliances had occurred in all 
three segments of the world pharmaceutical industry 
(among inventive – original pharmaceutical compa-
nies, generic producers and specialists). These alliances 
have created practically brand new pharmaceutical 
companies; meanwhile, some previously well-known 
ﬁrms have disappeared from the global market scene. 
For example, the world’s leading pharmaceutical com-
pany Pﬁzer has been created from ﬁve major interna-
tional players, such as Pﬁzer itself, Warner Lambert, 
Upjohn, Searle and Pharmacia. GlaxoSmithKline has 
emerged from ﬁve companies as well: Smith, Kline, 
Beecham, Glaxo and Wellcome. The world’s leading 
generic player, Israeli Teva, has acquired more than 10 
generic companies, including Lemmon, Gry, Prosintex, 
Biogal, Human, Biocraft, Pharmascience, Copley, No-
vofarm, Bayer Classics, Sicor and Ivax to form today’s 
Teva. German generic manufaturer Sandoz (part of 
the Swiss concern Novartis), as the second largest ge-
neric player worldwide, has acquired a major portion 
of other generic companies, such as Biochemie, Labi-
nca, Lagap, BASF Pharma (Knoll) Generics, Apothecon, 
Lek, Amifarma, Sabex, Hexal and Eon Labs., to mention 
just the most important and signiﬁcant ones. The U.S. 
generic major Barr Pharmaceuticals acquired Croatia’s 
leading pharmaceutical company Pliva in 2006. And 
finally, one of the leading U.S. generic companies 
Mylan has recently acquired German generic entity 
Merck Generics. 
In our research we found that the world pharmaceu-
tical industry is becoming increasingly oligopolistic. 
We may refer entirely to Knickerbocker’s theory of 
oligopolistic reaction, which says that oligopolistic 
companies, seeking to avoid destructive effects of 
competition, follow each other to new markets to 
protect their own interests. He outlines that the ac-
tion of one player creates the reaction of its competi-
tors, fuelling the process of oligopolization.13 We may 
conclude that Knickerbocker’s theory illustrates and 
explains perfectly the process of consolidation of the 
world pharmaceutical industry.  











Alliance-forging continues to speed up as pharmaceu-
tical companies try to follow their competitors’ strate-
gies of mergers and acquisitions (M&A) in an endeavor 
to maintain their global market position and long-term 
competitiveness. In our research we conducted a sur-
vey on the recent acquisitions and alliances of several 
world pharmaceutical companies in 2006 and 2007. 
This survey conﬁrms our conclusions of a rapid con-
solidation and oligopolization of the world pharma-
ceutical industry. 
It is evident that some stand-alone pharmaceutical 
companies are no longer capable of satisfying long-
term and ever-changing market needs or the expecta-
tions of their customers, nor can they invest as heavily 
into R&D and marketing activities in an attempt to 
bring new products to global markets and exploit 
them properly. If a particular pharmaceutical com-
pany is not able to perform the development cycle 
on its own, it has to look for a suitable partner to form 
a strategic alliance. Forging alliances among partners 
for the sake of maintaining long-term competitiveness 
is one of the most usable strategies in the world phar-
maceutical industry today. We may argue that pharma-
ceutical companies make alliances in order to create 
common synergies and better exploit their common 
assets, knowledge, product life cycles and moreover to 
improve their marketing management strategies. 
Thus, we may point out the following as crucial to 
the creation of common strategies of pharmaceutical 
companies: 
• research and development (R&D), to create new 
products, 
• products, to gain market shares and drive sales 
growth,
• markets, to create geographic and market expan-
sion,
• marketing and sales, as the implementation of mar-
keting and sales activities is essential for competing 
on global markets.
Table 6: Overview of the latest pharmaceutical alliances in the year 2006 and 2007
Target company taken over Acquirer Creation of synergies
Schering AG, Germany Bayer, Germany R&D, markets, marketing&sales
Hemofarm, Serbia Stada, Germany markets, products, sales
Serono, Switzerland Merck KGaA, Germany R&D, markets, marketing&sales
Schwarz Pharma, Germany UCB, Belgium R&D, products, markets, marketing&sales
Altana Pharma, Germany Nycomed, Denmark R&D, markets, products, marketing&sales
Hospira, U.S. Mayne Pharma, Australia products, markets, marketing&sales
Pliva, Croatia Barr Pharmaceuticals, U.S. markets, products, R&D (biogenerics), sales 
Kos Pharmaceuticals, U.S. Abbott, U.S. R&D, products, marketing&sales
MedImmune, U.S. AstraZeneca,  
United Kingdom
R&D, products (vaccines), marketing&sales
Organon BioSciences, the 
Netherlands
Schering-Plough, U.S. R&D, markets, products, marketing&sales
New River Pharmaceuticals, U.S. Shire Pharmaceuticals, 
United Kingdom 
products, R&D, marketing&sales
Tanox, U.S. Genentech, U.S. R&D, products, marketing&sales
Merck Generics, Germany Mylan, U.S. markets, products, marketing&sales
Group MAKIZ, Russian federation Stada, Germany markets, products, marketing&sales
Source: own estimation, according to companies’ oﬃcial data

























Due to the complexity of the pharmaceutical industry 
we may also say that pharmaceutical companies tend 
both to form alliances and to compete at the same 
time. They can cooperate on particular projects (for 
example in R&D) but may still compete strongly for 
particular market shares. This is the so-called C and C 
phenomenon that has been nicknamed “co-opetition” 
(cooperation and competition at the same time).14 
Pharmaceutical companies tend to internationalize 
and globalize their business activities sooner than 
they have done in the past due to market liberaliza-
tion, increased competitiveness and the need to reach 
considerable economies of scale. 
According to this, Svetličič proposes that “modern 
ways of internationalization with the aid of network 
formation and strategic alliances enable international-
ization without growth of companies. Today, compa-
nies decide for internationalization and alliances to:
• be closer to customers,
• increase eﬀectiveness,
• gain better access to technologies and knowledge 
(know-how),




IN THE WORLD 
PHARMACEUTICAL 
INDUSTRY
The world management guru Peter Drucker, who has 
especially emphasized the core importance of the 
marketing way of thinking and marketing manage-
ment for a successful, highly competitive long-term 
business performance of companies, has once said 
about globalization and globalization management: 
“In the years to come, there will be two types of top 
managers: those who would be able to think globally 
with strong marketing management commitment, 
and those jobless.” The marketing way of global 
thinking, performance and management thus enables 
companies to put customers in the center of all their 
business activities and to focus all business activities 
integrally on a common and ﬁnal goal – to be suc-
cessful in satisfying customers’ needs and to be better 
than competitors. 
We need to take into account that companies nowa-
days do not conduct their business activities on the 
markets with constant, known customers, competi-
tors and buyers, who do not change their preferred 
products. The companies of today, and moreover the 
companies of tomorrow, do business by battling with 
their fast-changing competitors, quick technological 
development, new and changing regulatory issues 
in the conditions of changing world trade policies, 
and with ever decreasingly loyal customers. We need 
to take into consideration the fact that today’s and 
tomorrow’s customers even more so have numerous 
oﬀers of diﬀerent products in each product category, 
and diﬀerent, ever-changing demands for a variety of 
product and service combinations and as well as for 
a variety of prices. With a rich and various oﬀer, cus-
tomers will invariably opt for such a product or service 
which enables them to optimally fulﬁll their individual 
needs and expectations. According to our research, 
it is no surprise that successful companies, and with 
this strategy they will be successful in the future as 
well, know how to satisfy their focused customers’ 
needs. Within such companies marketing and market-
ing management represent the business philosophy 
of a whole company instead of being just a separate 
function. 
This perfectly emphasizes Drucker,16 when he says 
“Marketing is so important that it cannot be a stand-
alone function. If we look upon it from the point of 
a ﬁnal result, i.e. from the point of view of the ﬁnal 
customer, marketing represents whole business, whole 
business performance. Care for marketing must go 
through all company structures. Business success is 
not dependent upon a producer, but upon a custom-
er.” For Drucker, a well-developed marketing manage-
ment concept should be the most important one in 
a company, prevailing over “innovativeness, organiza-
tion, ﬁnancial resources, physical sources, productivity, 
social responsibility and demand for proﬁt making”. 











We found out in our research that the marketing way 
of thinking and marketing management are especially 
important in the pharmaceutical industry as pharma-
ceutical companies tend to be market-oriented and 
proactive by emphasizing the advantage of their 
pharmaceutical products. While trying to communi-
cate within regulated frameworks, they tend to build 
strong brand names (trademarks) and to create long-
term loyalty to ﬁnal customers. It is decisive for them 
which product a doctor chooses and prescribes to the 
ﬁnal user – a patient, and how many times that patient 
will use it: just once or repeatedly, or even choosing a 
competitor’s product.
Thus, we may argue that marketing management is by 
no means the most important top or strategic busi-
ness function in the world pharmaceutical industry. 
However, due to fast-increasing competitiveness and 
globalization, it has been gaining in its strategic im-
portance. 
The concept of marketing management in a certain 
way clearly deﬁnes a company’s business philosophy. 
Here we may refer to and agree entirely with Corstjens’ 
statement17 that the pharmaceutical sector, despite 
being very speciﬁc in all aspects, is an ideal case to 
show “how the practice and usage of the marketing 
management concept directly relates to a very suc-
cessful business performance of this industrial sec-
tor”. 
According to our research, the marketing way of think-
ing and marketing management, besides the R&D 
function, is without any shadow of a doubt the most 
important function of innovative companies’ business 
performance. Since changes in the world today are 
so fast and profound, it is diﬃcult to follow them let 
alone predict their future course. This is especially sig-
niﬁcant for the world pharmaceutical industry. How-
ever, changes represent new challenges while also 
creating new business opportunities. Therefore, it is 
important to react and act quickly and to be proactive. 
So we may argue that it is crucial to be fast. A rapid 
and urgent adjustment is not merely the strategy to be 
adopted by smaller companies and countries but is a 
valid strategy of victorious survival for bigger systems, 
too, as changes in the world economy and globaliza-
tion are fast and tremendous. That is why we may ar-
gue that the systematic approach and the marketing 
way of thinking as well as marketing management are 
the decisive factors of strategic business success in a 
highly globalized and ever-changing world market-
place. 
We may refer nicely as well to Hamel and Prahalad, 
who outline the category of customers as the highest 
strategic priority of a company by saying that “A com-
pany that wants to be successful even tomorrow and 
wants to make proﬁts on tomorrow’s markets, must 
build up competitive advantages which will bring 
higher relevant value for tomorrow’s customers. If a 
company wants to be a leader, it must be capable to 
re-innovate its industrial segment and re-check its 
main strategies. If a company wants to be a leader in 
the future, it needs to learn thinking diﬀerently primar-
ily on four issues: customers, meaning of competitive-
ness, strategy and organizational structure. Companies 
which create future are those ones which constantly 
search for the ways to use their competitive advan-
tages in the new manner, in the new context and with 
a new goal, to satisfy future needs of the customers. 
If a company is not able to create future markets and 
ways to satisfy future needs of customers, it will ﬁnd 
itself on the magically spilled treadmill, hopelessly try-
ing to catch future competitors with falling proﬁts of 
past performances”.18
Some experiences and lessons from the global per-
spective of the world pharmaceutical industry could 
be beneﬁcial for the management of pharmaceutical 
companies in the transition countries of the CEE (Cen-
tral East European) region too. Taking into consider-
ation the current market position of these companies, 
some marketing management guidelines for their 
marketing management policies and strategies could 
be suggested. First of all, their management has to 
understand the true strategic value of the marketing 
management function and, in addition, that globaliza-
tion is a speedy, complex and deﬁnitely market-con-
ditioned and driven process, which greatly inﬂuences 
day-to-day activities but even more so strategic busi-
ness operations of pharmaceutical companies. Finally, 
these companies need to pay even more strategic at-
tention to marketing management if they want to be 

























successful business performers in the future as well. 
The market has been changing so fast that some 
companies do not even notice these changes; such 
companies are in real danger of being shaken up by 
a takeover process, or they simply lack the ability to 
compete on the regional, international, not to mention 
on the global market further along the way.  
We may say that world pharmaceutical companies 
conduct their business activities in a very turbulent 
environment, which requires constant adjustment to 
changes and quick ﬁnal action decisions. We are of 
the opinion that the pharmaceutical companies which 
want to be among global leaders and successful busi-
ness performers in the future need primarily to think 
comprehensively and differently about customers, 
markets, competitiveness, competitors and strategy in 
relation to structure so as to reach their targeted goals. 
They especially need to keep in mind the fact that the 
needs of tomorrow’s customers are diﬀerent from the 
needs of today’s customers and they do change fast 
and tremendously in relation to the elements and facts 
which are important to the pharmaceutical industry 
itself. In that respect we foresee the role of the market-
ing way of thinking and marketing management as a 
decisive, dominant and the most important strategic 
function of individual pharmaceutical companies. 
7. CONCLUSION
The purpose of this research paper was to investigate 
whether marketing management plays an important 
role in the operational and strategic performance in 
the world pharmaceutical industry. Using a variant of 
publicly available data and information, predominantly 
that on the business performance of the world phar-
maceutical industry, the world pharmaceutical markets 
and the development trends within the pharmaceuti-
cal industry in our research work, we have found out 
that the world pharmaceutical industry has changed 
profoundly in the last couple of years. We provide em-
pirical evidence that the intensive processes of concen-
tration and consolidation have continued in all three 
sectors of the world pharmaceutical industry. In order 
to explain this phenomenon properly, we have ana-
lyzed in detail the trends in the world pharmaceutical 
industry and key reasons for such developments. We 
have found out that intensive globalization processes 
deﬁnitely inﬂuence and reinforce a consolidation of the 
world pharmaceutical industry. Furthermore, we may 
argue that increased competitiveness and a changed 
structure of competitors conditioned by M&A pro-
cesses affect the strategic orientation of individual 
world pharmaceutical companies. The results of our 
research survey show that mergers and acquisitions 
prevail increasingly as a viable strategic orientation of 
the world pharmaceutical companies. However, tak-
ing into account the analyzed data, business perfor-
mance of scrutinized pharmaceutical companies and 
the outcomes of our research study, we may support 
the hypothesis that marketing management plays a 
dominant strategic role in the world pharmaceutical 
industry. Furthermore, we may even argue that a rapid 
consolidation of the world pharmaceutical industry is a 
clearly market-driven process and one conditioned by 
typical strategic marketing management issues, such 
as: a lack of brand new products, intense competitive-
ness, rapid globalization, increased global marketing 
and sales activities, changing structure of competitors 
and a ﬁerce ﬁght for global market shares and custom-
ers’ loyalty. 
This is why we may emphasize that the marketing way 
of thinking and marketing management should be-
come the most important strategic priorities of any 
pharmaceutical company that wants to be a successful 
business performer, maintain its long-term competi-
tiveness and ensure its long-term development cycle 
as well. According to our research ﬁndings, we may 
argue that marketing management is bound to play an 
even more important strategic role in future globaliza-
tion and concentration processes of the world phar-
maceutical industry which we foresee as continuing at 
an intense pace. If a pharmaceutical company does not 
understand or apply marketing management as a top 
priority strategic function, some time in the future it 
will most probably be taken over by a pharmaceutical 
company which values and uses marketing manage-
ment in its day-to-day as well as in its strategic busi-
ness activities. We may further conclude that a future 
strategic development of the world pharmaceutical 
industry will depend predominantly on the strategic 
marketing management issues that the pharmaceu-











tical companies will be able to understand, develop 
and apply properly in their operational and strategic 
business performance. 
In addition, we may point to several possible topics 
which might be interesting for future research in the 
ﬁeld of pharmaceutical industry, such as a correlation 
between ﬁnancial performance and investment into 
the marketing management activities of individual 
pharmaceutical companies, the way in which market-
ing management inﬂuences and supports the devel-
opment cycle of a particular pharmaceutical company 
and the roles of HRM (Human Resource Management) 
and cultural clashes in the process of consolidation and 
concentration of the world pharmaceutical industry, 
when faced with massive restructuring, down-sizing 
and cost-optimizing in the wake of M&A processes.  
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